We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ProQR Therapeutics NV | NASDAQ:PRQR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0295 | -1.52% | 1.9105 | 1.91 | 1.93 | 1.9899 | 1.85 | 1.93 | 50,893 | 17:28:08 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
December 27, 2017
PROQR THERAPEUTICS N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including ZIP Code, and Telephone Number,
Including Area Code, of Registrants Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On December 27, 2017, ProQR Therapeutics N.V. issued a press release announcing an extraordinary general meeting of shareholders and made available to its shareholders certain other materials in connection with such meeting.
Such materials are attached as exhibits to this Form 6-K and are incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PROQR THERAPEUTICS N.V. | ||||||
Date: December 29, 2017 | By: | /s/ Smital Shah | ||||
Smital Shah |
||||||
Chief Financial Officer |
EXHIBIT INDEX
Exhibit |
Description of Exhibit |
|
99.1 | Press Release dated December 27, 2017 | |
99.2 | Notice and Agenda for the 2018 Extraordinary General Meeting of Shareholders | |
99.3 | Explanatory Notes to the Agenda of the 2018 Extraordinary General Meeting of Shareholders | |
99.4 | Proxy Form | |
99.5 | Proposed Amendments to the Articles of Association |
1 Year ProQR Therapeutics NV Chart |
1 Month ProQR Therapeutics NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions